Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

International Journal of Cancer

Volumn 97, Issue 3, 2002, Pages 290-296

  Kwon, Ho Jeong ^a   Kim, Myoung Sook ^b   Kim, Min Jung ^a   Nakajima, Hidenori ^c   Kim, Kyu Won ^d  

^a Sejong University   (South Korea)

^b Pusan National University   (South Korea)

^c ASTELLAS PHARMA INC   (Japan)

^d Seoul National University   (South Korea)

Author keywords

Angiogenesis; Antitumor agent; FK228; Histone deacetylases

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; FR 901228; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MERLIN; NEUROFIBROMIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHICK EMBRYO; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HYPOXIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AORTA; CATTLE; CELL ADHESION; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; CHICK EMBRYO; CLINICAL TRIALS; COLLAGEN; DEPSIPEPTIDES; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HELA CELLS; HISTONE DEACETYLASES; HUMANS; LAMININ; LIGASES; MALE; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NEUROFIBROMIN 2; PEPTIDES, CYCLIC; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0037137896     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1602     Document Type: Article

References (41)

1. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
2. Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy
3. Endostatin: A promising drug for antiangiogenic therapy
4. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
5. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth
6. Eponemycin, a novel antibiotic, is a highly powerful angiogenesis inhibitor
7. Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis
8. Depudecin, a microbial metabolite containing two epoxide groups, exhibits anti-angiogenic activity in vivo
9. Thalidomide is an inhibitor of angiogenesis
10. Suppression of human microvascular endothelial cell invasion and morphogenesis with synthetic matrix inhibitors: Targeting angiogenesis with MMP inhibitors
11. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
12. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
13. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
14. Hypoxia stimulates myocardial RNA synthesis and histone acetylation
15. Histone acetylation in chromatin structure and transcription
16. Histone deacetylases, transcriptional control and cancer
17. The human histone deacetylase family
18. Histone deacetylase induce angiogenesis by negative regulation of tumor suppressor genes
19. Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase
20. Histone deacetylase inhibitors suppress IL-2-mediated gene expression before induction of apoptosis
21. Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation
22. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor
23. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family
24. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
25. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function
26. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties and antitumor activity
27. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice
28. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
29. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblast growth factor
30. Hypoxia induces capillary network formation in cultured bovine pulmonary microvessel endothelial cells
31. Adenosine and hypoxia stimulate proliferation and migration of endothelial cells
32. Role of endothelial nitric oxide synthase in endothelial cell migration
33. A rapid in vitro assay for quantitating the invasive potential of tumor cells
34. Shear stress modulates endothelial cell morphology and F-actin organization through the regulation of focal adhesion-associated proteins
35. Hypoxia and vascular endothelial growth factor stimulate angiogenic integrin expression in bovine retinal microvascular endothelial cells
36. Hypoxia induces endothelial cells to increase their adherence for neutrophils: Role of PAF
37. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
38. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
39. Inhibition of histone deacetylases: A new strategy to target epigenetic modifications for anticancer treatment
40. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: A new approach to anti-leukemia therapy
41. Histone deacetylase inhibitors as potential anti-skin cancer agents